Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...

We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Johnson & Johnson MedTech has announced U.S. 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

This week, Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche ...

AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by ...

Major indices were in the green early on Friday in what has otherwise been a losing week for the blue-chip Dow Jones.

J&J's Neutrogena Skin360 service faces class action lawsuit over biometric privacy violations, with a judge ruling against ...